Alcresta Therapeutics, Inc.
$170.2K 869 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Clozex Medical Inc
Clozex Medical Inc reported $170,186.74 across General Payments, Research, and Ownership to 6 physicians and teaching hospitals across 11 transactions.
- $170.2K Below-median payer
- All-tracks total
- 11 Below-median volume
- Transactions
- 6 Below-median reach
- Recipients
- +$161.90
- General Payments vs PY2023
Clozex Medical Inc reported $170,186.74 across all CMS Open Payments tracks (General + Research + Ownership) to 6 physicians and teaching hospitals in Program Year 2024 - ranking #1047 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $532.74, averaging $28.4K per recipient.
How Clozex Medical Inc's $170.2K all-tracks total breaks down
Clozex Medical Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
11/100
Total payments
F
12/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
10/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer clozex-medical-inc Clozex Medical Inc
$170.2K · #1047/1,925 · 0.0% industry · PY2024
- TOT $170.2K
- RANK #1047
- SHARE 0.0%
- TXN 11
- RCP 6
- CAT 1
- GEN $532.74
- ΔGEN +$161.90
- TOP1 34.1%
- PY 2024
Volume peers
Nearest volume peer: Alcresta Therapeutics, Inc. ($170.2K)
Clozex Medical Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Clozex Medical Inc's CMS-reported General Payments increased by $161.90 (+43.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: CLOZEX MEDICAL INCPY2023: CLOZEX MEDICAL INCPY2024: CLOZEX MEDICAL INC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $370.84
- PY2024
- $532.74
What the Data Shows for Clozex Medical Inc
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Clozex Medical Inc, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
The 1-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Food and Beverage" at $532.74, accounting for 100.0% of this company's General Payments and 6 transactions.
General Payment Breakdown by Type
"Food and Beverage" leads Clozex Medical Inc's 1-category general-payment breakdown at $532.74, 100.0% of the reported total.
How Clozex Medical Inc divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $532.74 | 6 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $519.41 (97.5%) of $532.74 in this company's General Payments records across 6 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Clozex Medical Inc
The five named recipients with the highest reported General Payments from this company
- 1
Michael Kluska
$181.73 across 1 reported transactions
- 2
Daniel Ralston
$148.11 across 1 reported transactions
- 3
John Lazor
$93.78 across 1 reported transactions
- 4
Dottie Planeta
$82.46 across 1 reported transactions
- 5
Julia Wetherhold
$13.33 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Clozex Medical Inc ranks #1047 of 1,925 by total payments (bottom 46% by spend) but is notably more concentrated than that alone would suggest -- #647 of 1,838 by HHI (top 35% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Boehringer Ingelheim RCV GmbH & Co KG : $63.7K total payments, HHI 2525
- Oxford Performance Materials, Inc. : $21.8K total payments, HHI 2520
- Avirmax Biopharma, Inc : $631.49 total payments, HHI 2519
- IBSA Institut Biochimique SA : $50.0K total payments, HHI 2512
- Ignite Orthomotion LLC : $27.3K total payments, HHI 2504
- NuMED for Children, LLC : $120.0K total payments, HHI 2500
- Clozex Medical Inc (this company) : $532.74 total payments, HHI 2499
- Veran Medical Technologies, Inc. : $3.6K total payments, HHI 2498
- Surgical Fusion Inc. : $29.8K total payments, HHI 2497
- Corentec America,Inc. : $280.2K total payments, HHI 2497
- Civica, Inc. : $1.1K total payments, HHI 2493
- Atlas Spine, Inc. : $31.3K total payments, HHI 2488
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Clozex Medical Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Clozex Medical Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Clozex Medical Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Draeger Medical Systems, Inc
$169.2K 95 recipients
Compare payment profiles
Quanta Dialysis Technologies Inc
$169.2K 2 recipients
Compare payment profiles
Hexal AG
$168.9K 19 recipients
Compare payment profiles
Carl Zeiss Meditec Digital Innovations LLC
$167.7K 34 recipients
Compare payment profiles
Bioprotect Medical, Inc.
$165.6K 954 recipients
Compare payment profiles
Put this to use
Clozex Medical Inc ranks #1047 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Clozex Medical Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.